Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin. An inverter, a propulsive electric motor, and an air compressor are supplied with electric power from the first power supply line. A \u201ctherapeutic peptide composition\u201d comprises a \u201ccarrier peptide\u201d and a \u201ccargo peptide.